Home Cart Sign in  
Chemical Structure| 1009298-59-2 Chemical Structure| 1009298-59-2

Structure of Vistusertib
CAS No.: 1009298-59-2

Chemical Structure| 1009298-59-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Vistusertib (AZD2014) is an ATP-competitive mTOR inhibitor with an IC50 of 2.81 nM, inhibiting both mTORC1 and mTORC2 complexes.

Synonyms: AZD2014

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Vistusertib

CAS No. :1009298-59-2
Formula : C25H30N6O3
M.W : 462.54
SMILES Code : O=C(NC)C1=CC=CC(C2=NC3=NC(N4[C@@H](C)COCC4)=NC(N5[C@@H](C)COCC5)=C3C=C2)=C1
Synonyms :
AZD2014
MDL No. :MFCD22628784
InChI Key :JUSFANSTBFGBAF-IRXDYDNUSA-N
Pubchem ID :25262792

Safety of Vistusertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Vistusertib

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • mTOR

    mTOR, IC50:2.8 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Vero kidney epithelial cells 25 nM 72 h Reduced SARS-CoV-2 replication PMC7994801
GL261 cells 250 nM 72 h To evaluate the synergistic effect of Vistusertib with BET inhibitor Birabresib, the results showed that the combination of Vistusertib and Birabresib had potential synergy. PMC10433015
MPM/AF 3D co-culture spheroids 10 µM 72 h To test the single-agent efficacy of Vistusertib in MPM/AF 3D co-culture spheroids, results showed its efficacy was superior to the cisplatin/pemetrexed combination. PMC10632403
MCF7 20 nM 72 h To evaluate the effect of Vistusertib on the proliferation of MCF7 cells, results showed a concentration-dependent decrease in proliferation in the presence of E2. PMC6894349
MCF7 LTEDY537C 50 nM 72 h To evaluate the effect of Vistusertib on the proliferation of MCF7 LTEDY537C cells, results showed sensitivity in both the presence and absence of E2. PMC6894349
MCF7 LTEDwt 75 nM 72 h To evaluate the effect of Vistusertib on the proliferation of MCF7 LTEDwt cells, results showed a concentration-dependent decrease in proliferation. PMC6894349
MCF7 TAMR 85 nM 72 h To evaluate the effect of Vistusertib on the proliferation of MCF7 TAMR cells, results showed a concentration-dependent decrease in proliferation. PMC6894349
MCF7 ICIR 50 nM 72 h To evaluate the effect of Vistusertib on the proliferation of MCF7 ICIR cells, results showed a concentration-dependent decrease in proliferation. PMC6894349

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Nf2/Bap1/Cdkn2a triple-floxed mice Intraperitoneal injection 15 mg/kg 3 weeks (7 days on, 2 days off, 5 days on, 2 days off, 5 days on) To test the efficacy of Vistusertib as a single agent in a mouse model, results showed it did not significantly improve survival. PMC10632403
Mice HBCx34 OvaR PDX model Oral gavage 15 mg/kg Daily for 90 days To evaluate the effect of Vistusertib alone or in combination with Fulvestrant on tumour progression in the HBCx34 OvaR PDX model, results showed that Vistusertib alone or in combination with Fulvestrant significantly inhibited tumour progression. PMC6894349

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02619864 Glioblastoma Multiforme PHASE1 COMPLETED 2020-02-25 Tom Baker Cancer Centre, Calga... More >>ry, Alberta, T2N 4N2, Canada|CancerCare Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, B3H 1V7, Canada|University Health Network, Toronto, Ontario, M5G 2M9, Canada Less <<
NCT03071874 Meningioma PHASE2 UNKNOWN 2024-07-25 Northwestern University, Chica... More >>go, Illinois, 60611, United States|Massachusetts general Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less <<
NCT03082833 Cancer of Stomach PHASE2 TERMINATED 2018-11-16 Samsung Medical Center, Seoul,... More >> 06351, Korea, Republic of Less <<
NCT02398747 Advanced Solid Malignancies PHASE1 COMPLETED 2024-04-12 Research Site, Chuo-ku, 104-00... More >>45, Japan|Research Site, Kashiwa, 277-8577, Japan Less <<
NCT02064608 Prostate Cancer PHASE1 COMPLETED 2025-06-18 Cambridge University Hospitals... More >> NHS Foundation Trust, Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom Less <<
NCT03061708 Stomach Neoplasms PHASE2 TERMINATED 2018-11-16 Samsung Medical Center, Seoul,... More >> Korea, Republic of Less <<
NCT02831257 Neurofibromatosis 2|Meningioma PHASE2 COMPLETED 2020-10-01 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02115, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT01026402 Advanced Solid Malignancies PHASE1 COMPLETED 2025-08-14 Research Site, Manchester, Uni... More >>ted Kingdom|Research Site, Sutton, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.16mL

0.43mL

0.22mL

10.81mL

2.16mL

1.08mL

21.62mL

4.32mL

2.16mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories